ImmunoMet Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Employees
  • 7
Employees
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $7M
Latest Deal Amount
  • Investors
  • 11

ImmunoMet General Information

Description

Developer of novel anti-tumor and immuno-oncology therapies designed to treat cancer patients. The company's therapies include oncology drugs and metabolic regulators to increase patient survival by disrupting cancer metabolism and enhancing anti-cancer immunity targeting the cellular metabolism of drug-resistant cancer subpopulations and immuno-suppressors of anti-cancer effector T cells, enabling healthcare providers to provide long-term survival and quality of life for cancer patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • JLABS at Texas Medical Center
  • 2450 Holcombe Boulevard
  • Houston, TX 77021
  • United States
+1 (346) 000-0000

ImmunoMet Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ImmunoMet Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 08-Feb-2021 $7M 000.00 Completed Clinical Trials - Phase 1
5. Early Stage VC (Series B) 05-Feb-2020 000.00 000.00 000.00 Completed Clinical Trials - Phase 1
4. Early Stage VC (Series B) 07-Mar-2017 000 000.00 0000 Completed Clinical Trials - General
3. Accelerator/Incubator 02-Mar-2016 00.00 Completed Startup
2. Early Stage VC (Series A) 05-Feb-2016 $5.2M $6.2M 000.00 Completed Startup
1. Seed Round 01-Aug-2015 $996K $996K 00.000 Completed Startup
To view ImmunoMet’s complete valuation and funding history, request access »

ImmunoMet Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A 0,000,000 00.000000 00 00 00 00 00.000
Seed 800,000 $0.001000 $1.25 $1.25 1x $1.25 17.04%
To view ImmunoMet’s complete cap table history, request access »

ImmunoMet Executive Team (16)

Name Title Board Seat Contact Info
Benjamin Cowen Ph.D President, Chief Executive Officer & Board Member
Michael Bell Chief Financial Officer
Dean Welsch Ph.D Chief Scientific Officer
Anthony Horning Head of Business Development, Licensing & Business Advisor
Jae-Ho Cheong MD Advisor
You’re viewing 5 of 16 executive team members. Get the full list »

ImmunoMet Board Members (9)

Name Representing Role Since
Andrew Kim Incon Company Board Member 000 0000
Benjamin Cowen Ph.D ImmunoMet President, Chief Executive Officer & Board Member 000 0000
Bongyong Lee Ph.D Self Board Member 000 0000
Jae-Joon Kim Mirae Asset Venture Investment Board Member 000 0000
Paul Lammers MD Self Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

ImmunoMet Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ImmunoMet Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Incon Company Corporation Minority 000 0000 000000 0
InterVest Venture Capital Minority 000 0000 000000 0
NHN Capital Venture Capital Minority 000 0000 000000 0
SL Investment Venture Capital Minority 000 0000 000000 0
JLABS Accelerator/Incubator 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »